
FDA Approves Biocon Biologics' Bevacizumab Biosimilar
Biocon Biologics expands its oncology biosimilar roster after gaining FDA approval for Jobevne (bevacizumab-nwgd), the sixth biosimilar referencing Avastin (bevacizumab).1,2 The new recombinant humanized monoclonal antibody targeting vascular endothelial …